Iberdomide (also known as BMS-986382) is a medication being studied for treating relapsed or refractory multiple myeloma. It belongs to a new class of drugs that helps the immune system fight cancer cells.

Daratumumab is an antibody medication that targets specific proteins on myeloma cells. It works by helping the body’s immune system recognize and destroy cancer cells in multiple myeloma.

Dexamethasone is a corticosteroid medication that helps reduce inflammation and suppress the immune system. In multiple myeloma treatment, it is often combined with other medications to enhance their effectiveness.

Bortezomib is a targeted therapy that belongs to a class of drugs called proteasome inhibitors. It works by blocking certain proteins that help cancer cells survive, causing the cancer cells to die.

Multiple Myeloma – A blood cancer that develops in plasma cells, which are white blood cells that help fight infections. In this condition, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. These abnormal cells produce large amounts of defective antibodies that build up in the body. The disease typically affects multiple bones in the body, hence its name. Over time, the condition can damage bones, lead to high blood calcium levels, and cause problems with blood cell production. The disease often progresses through cycles of active disease and remission.

Relapsed Multiple Myeloma – A form of multiple myeloma that has returned after a period of remission or response to previous treatment. The disease shows signs of progression after a period when it was under control.

Refractory Multiple Myeloma – A form of multiple myeloma that does not respond to current therapy, or stops responding during treatment. The disease continues to progress despite ongoing treatment efforts.